As Partners Co Ltd

As Partners Co Ltd maintains a liquidity position with a current ratio of 1.24, indicating a moderate ability to meet short-term obligations, supported by cash and equivalents of 5,707,562,000 JPY. The company's debt-to-equity ratio of 2.38 suggests a relatively high reliance on debt financing, which could increase financial risk.

The company's profitability is reflected in a return on equity of 4.84% and a return on assets of 0.72%, both of which are below the industry median for healthcare facilities and services, indicating room for improvement in capital efficiency and asset utilization.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue concentration is primarily within its core healthcare services and equipment operations.

The company's growth trajectory is modest, with a current FY revenue of 4,330,794,000 JPY and a mean analyst revenue estimate of 24,000,000,000 JPY for the next fiscal year, suggesting a significant growth expectation. However, the actual revenue in the last fiscal year was 17,917,000,000 JPY, which is higher than the current FY revenue, indicating potential volatility or seasonal factors.

Risk factors for the company are currently assessed as low for both liquidity and dilution, with no immediate filing-based flags detected. The company's capital structure, with a high debt-to-equity ratio, may pose a risk if interest rates rise or if the company's cash flow is disrupted.

Recent events, including analyst estimates and actual performance, show that the company's last actual EPS was 269.74 JPY, slightly below the mean estimate of 296.00 JPY, indicating a potential for earnings to meet or exceed expectations in the next reporting period.

This is the first analysis for As Partners Co Ltd (160A.T), meaning there is no prior basis for computing material changes or deltas in the company's profile. Consequently, no specific shifts in operational metrics, financial performance, or strategic direction can be identified from the available data. The company currently shows zero recorded officers, analysts, index memberships, or top holders in the provided dataset. This absence of data points suggests a lack of established public tracking or reporting infrastructure for the entity within the current monitoring framework. Cross-source signals indicate minimal activity, with only two dispatches recorded over the 30-day period ending in July 2026: one on July 2 and another on July 15. All other days in this window show zero dispatches, and no sentiment data is available for these sparse events. Given the lack of historical data and current activity, the significance of these findings is limited to establishing a baseline. Future analysis will depend on the emergence of new data points from sources such as financials [doc:160a.t-ha-financials] or estimates [doc:160a.t-ha-estimates] to determine any material developments.

Operating income surged 303.6% year-over-year, demonstrating significant operational leverage and improved core profitability for the company.

Net income increased by 145.3% year-over-year, indicating strong bottom-line growth and effective cost management strategies.

Return on equity of 4.84% exceeds the healthcare facilities cohort median of 4.56%, showing superior capital efficiency.

Revenue grew 34.2% year-over-year, highlighting robust top-line expansion and increasing market demand for services.

Cash conversion ratio of 29.78 is best-in-class compared to the cohort median of 1.35, reflecting high earnings quality.

Debt-to-equity ratio of 2.38 is in the bottom quartile versus the cohort median of 0.32, signaling high financial leverage risk.

Free cash flow turned significantly negative at -3.6 billion JPY, indicating severe cash burn and liquidity pressure.

Revenue ¥5.48B, +53,3% YoY; Operating income +867,0% YoY.

• ▍Revenue ¥5.48B, +53,3% YoY
• ▍Operating income +867,0% YoY
• ▍Net income +3 130,9% YoY
• ▍Net margin 0.9%

Revenue ¥4.62B, −30,0% YoY; Operating income −91,3% YoY.

• ▍Revenue ¥4.62B, −30,0% YoY
• ▍Operating income −91,3% YoY
• ▍Net income −90,2% YoY
• ▍Net margin 2.0%

Revenue ¥8.99B, +125,5% YoY; Operating income +7 223,9% YoY.

• ▍Revenue ¥8.99B, +125,5% YoY
• ▍Operating income +7 223,9% YoY
• ▍Net income +3 241,8% YoY
• ▍Net margin 11.1%

Revenue ¥3.76B, −13,2% YoY; Operating income −104,2% YoY.

• ▍Revenue ¥3.76B, −13,2% YoY
• ▍Operating income −104,2% YoY
• ▍Net income −55,7% YoY
• ▍Net margin 1.4%

Revenue ¥3.57B; Operating income ¥8.2M.

• ▍Revenue ¥3.57B
• ▍Operating income ¥8.2M
• ▍Net margin 0.0%

Revenue ¥6.60B; Operating income ¥1.32B.

• ▍Revenue ¥6.60B
• ▍Operating income ¥1.32B
• ▍Net margin 14.2%

Revenue ¥3.99B; Operating income -¥19.8M.

• ▍Revenue ¥3.99B
• ▍Operating income -¥19.8M
• ▍Net margin -0.8%

Revenue ¥17.92B, +4,5% YoY; Operating income +62,4% YoY.

• ▍Revenue ¥17.92B, +4,5% YoY
• ▍Operating income +62,4% YoY
• ▍Net income +69,8% YoY
• ▍Free cash flow −527,2% YoY
• ▍Net margin 5.3%